After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 wasn’t slow—it was actually quite normal. “This is a really ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

SailPoint, Inc. (SAIL) has filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement. SAIL provides a range of identity management and security ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood cancer.